13 results match your criteria Current Cancer Therapy Reviews[Journal]

  • Page 1 of 1

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.

Curr Cancer Ther Rev 2014;10(2):70-79

Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

Clonal heterogeneity and clonal evolution have emerged as critical concepts in the field of oncology over the past four decades, largely thanks to the implementation of novel technologies such as comparative genomic hybridization, whole genome/exome sequencing and epigenetic analysis. Along with the identification of cancer stem cells in the majority of neoplasia, the recognition of intertumor and intratumor variability has provided a novel perspective to understand the mechanisms behind tumor evolution and its implication in terms of treatment failure and cancer relapse or recurrence. First hypothesized over two decades ago, clonal heterogeneity and clonal evolution have been confirmed in multiple myeloma (MM), an incurable cancer of plasma cells, almost universally preceded by a pre-malignant conditioned named monoclonal gammopathy of undetermined significance (MGUS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339471002141124121404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334389PMC
January 2014
11 Reads

Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct.

Curr Cancer Ther Rev 2014 Jan;10(2):97-218

Department of Surgery, University of Texas Medical Branch, Galveston, TX, 77555 USA.

Cells in the stromal microenvironment facilitate colorectal cancer (CRC) progression and "co-evolve" with the epithelial cancer cells. Genetic and epigenetic differences between normal colorectal mucosa fibroblasts (NF) and carcinoma-associated fibroblasts (CAF) are not known. The aim of this study is to identify differentially expressed genes and promoter methylation between NF and CAF in human CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339471002141124123103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270051PMC
January 2014
10 Reads

Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma.

Curr Cancer Ther Rev 2012 May;8(2):116-127

Experimental Oncology Laboratory, Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, University of Tennesse, Knoxville, TN, USA.

Small airway epithelial cells from, which most pulmonary adenocarcinomas (PACs) derive, and pancreatic duct epithelia, from which pancreatic ductal adenocarcinomas (PDACs) originate, share the ability to synthesize and release bicarbonate. This activity is stimulated in both cell types by the α7nicotinic acetylcholine receptor (α7nAChR)-mediated release of noradrenaline and adrenaline, which in turn activate β-adrenergic receptor (β-AR) signaling, leading to the cAMP-dependent release of bicarbonate. The same signaling pathway also stimulates a complex network of intracellular signaling cascades which regulate the proliferation, migration, angiogenesis and apoptosis of PAC and PDAC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339412800675351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691862PMC
May 2012
6 Reads

The Current and Future Therapies for Human Osteosarcoma.

Curr Cancer Ther Rev 2013 Feb;9(1):55-77

Molecular Oncology Laboratory, Department of Orthopaedic Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA.

Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in adults and children. As sarcomas are more common in adolescents and young adults than most other forms of cancer, there are a significant number of years of life lost secondary to these malignancies. OS is associated with a poor prognosis secondary to a high grade at presentation, resistance to chemotherapy and a propensity to metastasize to the lungs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1573394711309010006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730918PMC
February 2013
35 Reads

Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Curr Cancer Ther Rev 2011 Nov;7(4):319-327

University of Wisconsin Paul P Carbone Comprehensive Cancer Center 600 Highland Ave Madison WI, 537192.

As therapeutic options and supportive care for the treatment of neoplastic disease have improved, there has been an associated increase in the incidence of leptomeningeal disease. In this review, the clinical presentation, natural history, diagnostic evaluation, and treatment options for this often devastating sequela of solid tumors, lymphoma, and leukemia will be summarized. The therapeutic efficacy of ionizing radiation, systemic agents, and intrathecal drugs will be examined from the existing literature. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/openurl/content.php?genre=articl
Publisher Site
http://dx.doi.org/10.2174/157339411797642597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523178PMC
November 2011
9 Reads

DNA Vaccines for Prostate Cancer.

Curr Cancer Ther Rev 2012 Nov;8(4):254-263

Department of Medicine, University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, Madison, WI 53705, USA.

Delivery of plasmid DNA encoding an antigen of interest has been demonstrated to be an effective means of immunization, capable of eliciting antigen-specific T cells. Plasmid DNA vaccines offer advantages over other anti-tumor vaccine approaches in terms of simplicity, manufacturing, and possibly safety. The primary disadvantage is their poor transfection efficiency and subsequent lower immunogenicity relative to other genetic vaccine approaches. Read More

View Article

Download full-text PDF

Source
http://openurl.ingenta.com/content/xref?genre=article&is
Publisher Site
http://dx.doi.org/10.2174/157339412804143113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935480PMC
November 2012
12 Reads

Targeting lentiviral vectors for cancer immunotherapy.

Curr Cancer Ther Rev 2011 Nov;7(4):248-260

Division of Infection and Immunity, Medical School of the Royal Free and University College London, 46 Cleveland Street, London W1T 4JF, United Kingdom.

Delivery of tumour-associated antigens (TAA) in a way that induces effective, specific immunity is a challenge in anti-cancer vaccine design. Circumventing tumour-induced tolerogenic mechanisms in vivo is also critical for effective immunotherapy. Effective immune responses are induced by professional antigen presenting cells, in particular dendritic cells (DC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339411797642605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442241PMC
November 2011
18 Reads

microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis.

Curr Cancer Ther Rev 2011 Aug;7(3):176-183

Department of Medicine - Division of Hematology/Oncology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.

The failed outcome of autologous bone marrow transplantation for breast cancer opens the field for investigations. This is particularly important because the bone marrow could be a major source of cancer cells during tertiary metastasis. This review discusses subsets of breast cancer cells, including those that enter the bone marrow at an early period of disease development, perhaps prior to clinical detection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339411796234915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163384PMC
August 2011
11 Reads

Angiogenin as a molecular target for the treatment of prostate cancer.

Curr Cancer Ther Rev 2011 May;7(2):83-90

Department of Pathology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.

Angiogenin (ANG), a 14 kDa angiogenic ribonuclease, is upregulated in human prostate cancers, especially in hormone refractory diseases, and is the highest upregulated gene in Akt-driven prostate intraepithelial neoplasia (PIN) in mice. ANG has been shown to undergo nuclear translocation in both prostate cancer cells and cancer-associated endothelial cells where it binds to the promoter region of ribosomal DNA (rDNA) and stimulates ribosomal RNA (rRNA) transcription. ANG thus plays an essential role in prostate cancer progression by stimulating both cancer cell proliferation and tumor angiogenesis. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131147PMC
May 2011
9 Reads

Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances.

Curr Cancer Ther Rev 2010 Nov;6(4):294-307

Center for Molecular Biology of Oral Diseases, College of Dentistry, University of Illinois at Chicago, Chicago, IL.

Even though lymph node metastasis accounts for the vast majority of cancer death in patients with oral cancer (OC), the molecular mechanisms of lymph node metastasis remain elusive. Genome-wide microarray analyses and functional studies in vitro and in vivo, along with detailed clinical observations, have identified a number of molecules that may contribute to lymph node metastasis. These include lymphangionenic cytokines, cell adhesion molecules, basement membrane-interacting molecules, matrix enzymes and relevant downstream signaling pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339410793358066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122885PMC
November 2010
9 Reads

Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS.

Curr Cancer Ther Rev 2009 Nov;5(4):310-314

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

There is growing evidence for a role of the hemopoietic microenvironment in the pathophysiology of myelodysplastic syndromes (MDS). Effects of various cytokines on the marrow microenvironment of patients with MDS have been studied. Autoimmunity, i. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840261PMC
November 2009
6 Reads

Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Curr Cancer Ther Rev 2006 Aug;2(3):255-270

Department of Pharmacology and Toxicology, Dartmouth Medical School, and the Norris Cotton Cancer Center, Dartmouth Hitchcock-Medical Center, Hanover, NH 03755, USA.

Treatment of testicular germ cell tumors (TGCTs) has been a success primarily due to the exquisite responsiveness of this solid tumor to cisplatin-based therapy. Despite the promise of cure for the majority of TGCT patients, the effectiveness of therapy for some patients is limited by toxicity and the problem of resistance. There is compelling rationale to further understand the biology of TGCTs in order to better treat other solid tumors and to address the shortcomings of present TGCT therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157339406777934681DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904303PMC
August 2006
8 Reads

Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy.

Curr Cancer Ther Rev 2006 Aug;2(3):271-279

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425.

Bone marrow (BM) suppression is the important dose-limiting side effect of chemotherapy and radiotherapy for cancer. Although acute myelosuppression is an immediate concern for patients undergoing cancer therapy, its management has been improved significantly in recent years by the use of various hematopoietic growth factors. However, many patients receiving chemotherapy and/or ionizing radiation (IR) also develop residual (or long-term) BM injury (a sustained decrease in HSC reserves due to an impairment in HSC self-renewal) after the recovery from acute myelosuppression. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779029PMC
August 2006
8 Reads
  • Page 1 of 1